Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) Enterprise Value (2022 - 2026)

Stoke Therapeutics has reported Enterprise Value over the past 5 years, most recently at -$84.7 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 33.85% year-over-year to -$84.7 million; the TTM value through Dec 2025 reached -$84.7 million, up 33.85%, while the annual FY2025 figure was -$84.7 million, 33.85% up from the prior year.
  • Enterprise Value for Q4 2025 was -$84.7 million at Stoke Therapeutics, down from -$83.4 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$83.4 million in Q3 2025 and troughed at -$357.3 million in Q1 2025.
  • A 5-year average of -$202.8 million and a median of -$214.7 million in 2023 define the central range for Enterprise Value.
  • On a YoY basis, Enterprise Value climbed as much as 47.53% in 2025 and fell as far as 100.09% in 2025.
  • Year by year, Enterprise Value stood at -$219.8 million in 2021, then fell by 4.45% to -$229.6 million in 2022, then rose by 12.28% to -$201.4 million in 2023, then skyrocketed by 36.41% to -$128.1 million in 2024, then surged by 33.85% to -$84.7 million in 2025.
  • Business Quant data shows Enterprise Value for STOK at -$84.7 million in Q4 2025, -$83.4 million in Q3 2025, and -$101.5 million in Q2 2025.